Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery

Timothy Fabian, Stephen R. Zellner, Alan Gazzaniga, Charles Hanna, Ronald Lee Nichols, Kenneth Waxman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The present study was performed in two phases. In phase I, 112 patients were randomized to either 2 g cefotetan as a single prophylactic dose or 2 g cefoxitin every 6 hours for a maximum of 4 doses; phase II included 148 patients who were randomized to either 1 g cefotetan as a single dose or cefoxitin dosed as in phase I. The randomization was 2:1 cefotetan to cefoxitin in both phases. Nonevaluability rates were 10 percent for the cefotetan patients and 22 percent for the cefoxitin patients, the majority being due to dosing errors. Demographic characteristics demonstrated 88 percent to be female, 81 percent to be less than 65 years of age, and the average weight to be 165 lb. There were no differences in these characteristics among the groups. Common duct exploration was performed in 6 percent of the 2 g cefotetan patients, 9 percent in the 1 g cefotetan patients, and 13 percent in the 2g cefoxitin patients. There were five clinical failures of prophylaxis: one wound infection in the 2 g cefotetan patients, one wound infection and one drain tract infection in the 1 g cefotetan patients, and one wound infection and one case of cholangitis in the 2 g cefoxitin patients. The clinical success rates were 98 percent in the 2 g cefotetan patients, 98 percent in the 1 g cefotetan patients, and 97 percent in the 2 g cefoxitin patients.

Original languageEnglish (US)
Pages (from-to)77-80
Number of pages4
JournalThe American Journal of Surgery
Volume155
Issue number5 SUPPL.
DOIs
StatePublished - May 31 1988

Fingerprint

Cefotetan
Cefoxitin
Multicenter Studies
Wound Infection
Cholangitis
Random Allocation

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Fabian, T., Zellner, S. R., Gazzaniga, A., Hanna, C., Nichols, R. L., & Waxman, K. (1988). Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery. The American Journal of Surgery, 155(5 SUPPL.), 77-80. https://doi.org/10.1016/S0002-9610(88)80218-6

Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery. / Fabian, Timothy; Zellner, Stephen R.; Gazzaniga, Alan; Hanna, Charles; Nichols, Ronald Lee; Waxman, Kenneth.

In: The American Journal of Surgery, Vol. 155, No. 5 SUPPL., 31.05.1988, p. 77-80.

Research output: Contribution to journalArticle

Fabian, T, Zellner, SR, Gazzaniga, A, Hanna, C, Nichols, RL & Waxman, K 1988, 'Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery', The American Journal of Surgery, vol. 155, no. 5 SUPPL., pp. 77-80. https://doi.org/10.1016/S0002-9610(88)80218-6
Fabian T, Zellner SR, Gazzaniga A, Hanna C, Nichols RL, Waxman K. Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery. The American Journal of Surgery. 1988 May 31;155(5 SUPPL.):77-80. https://doi.org/10.1016/S0002-9610(88)80218-6
Fabian, Timothy ; Zellner, Stephen R. ; Gazzaniga, Alan ; Hanna, Charles ; Nichols, Ronald Lee ; Waxman, Kenneth. / Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery. In: The American Journal of Surgery. 1988 ; Vol. 155, No. 5 SUPPL. pp. 77-80.
@article{e56ff4df438f4a2bbedf76a819a2191c,
title = "Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery",
abstract = "The present study was performed in two phases. In phase I, 112 patients were randomized to either 2 g cefotetan as a single prophylactic dose or 2 g cefoxitin every 6 hours for a maximum of 4 doses; phase II included 148 patients who were randomized to either 1 g cefotetan as a single dose or cefoxitin dosed as in phase I. The randomization was 2:1 cefotetan to cefoxitin in both phases. Nonevaluability rates were 10 percent for the cefotetan patients and 22 percent for the cefoxitin patients, the majority being due to dosing errors. Demographic characteristics demonstrated 88 percent to be female, 81 percent to be less than 65 years of age, and the average weight to be 165 lb. There were no differences in these characteristics among the groups. Common duct exploration was performed in 6 percent of the 2 g cefotetan patients, 9 percent in the 1 g cefotetan patients, and 13 percent in the 2g cefoxitin patients. There were five clinical failures of prophylaxis: one wound infection in the 2 g cefotetan patients, one wound infection and one drain tract infection in the 1 g cefotetan patients, and one wound infection and one case of cholangitis in the 2 g cefoxitin patients. The clinical success rates were 98 percent in the 2 g cefotetan patients, 98 percent in the 1 g cefotetan patients, and 97 percent in the 2 g cefoxitin patients.",
author = "Timothy Fabian and Zellner, {Stephen R.} and Alan Gazzaniga and Charles Hanna and Nichols, {Ronald Lee} and Kenneth Waxman",
year = "1988",
month = "5",
day = "31",
doi = "10.1016/S0002-9610(88)80218-6",
language = "English (US)",
volume = "155",
pages = "77--80",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5 SUPPL.",

}

TY - JOUR

T1 - Multicenter open trial of cefotetan and cefoxitin in elective biliary surgery

AU - Fabian, Timothy

AU - Zellner, Stephen R.

AU - Gazzaniga, Alan

AU - Hanna, Charles

AU - Nichols, Ronald Lee

AU - Waxman, Kenneth

PY - 1988/5/31

Y1 - 1988/5/31

N2 - The present study was performed in two phases. In phase I, 112 patients were randomized to either 2 g cefotetan as a single prophylactic dose or 2 g cefoxitin every 6 hours for a maximum of 4 doses; phase II included 148 patients who were randomized to either 1 g cefotetan as a single dose or cefoxitin dosed as in phase I. The randomization was 2:1 cefotetan to cefoxitin in both phases. Nonevaluability rates were 10 percent for the cefotetan patients and 22 percent for the cefoxitin patients, the majority being due to dosing errors. Demographic characteristics demonstrated 88 percent to be female, 81 percent to be less than 65 years of age, and the average weight to be 165 lb. There were no differences in these characteristics among the groups. Common duct exploration was performed in 6 percent of the 2 g cefotetan patients, 9 percent in the 1 g cefotetan patients, and 13 percent in the 2g cefoxitin patients. There were five clinical failures of prophylaxis: one wound infection in the 2 g cefotetan patients, one wound infection and one drain tract infection in the 1 g cefotetan patients, and one wound infection and one case of cholangitis in the 2 g cefoxitin patients. The clinical success rates were 98 percent in the 2 g cefotetan patients, 98 percent in the 1 g cefotetan patients, and 97 percent in the 2 g cefoxitin patients.

AB - The present study was performed in two phases. In phase I, 112 patients were randomized to either 2 g cefotetan as a single prophylactic dose or 2 g cefoxitin every 6 hours for a maximum of 4 doses; phase II included 148 patients who were randomized to either 1 g cefotetan as a single dose or cefoxitin dosed as in phase I. The randomization was 2:1 cefotetan to cefoxitin in both phases. Nonevaluability rates were 10 percent for the cefotetan patients and 22 percent for the cefoxitin patients, the majority being due to dosing errors. Demographic characteristics demonstrated 88 percent to be female, 81 percent to be less than 65 years of age, and the average weight to be 165 lb. There were no differences in these characteristics among the groups. Common duct exploration was performed in 6 percent of the 2 g cefotetan patients, 9 percent in the 1 g cefotetan patients, and 13 percent in the 2g cefoxitin patients. There were five clinical failures of prophylaxis: one wound infection in the 2 g cefotetan patients, one wound infection and one drain tract infection in the 1 g cefotetan patients, and one wound infection and one case of cholangitis in the 2 g cefoxitin patients. The clinical success rates were 98 percent in the 2 g cefotetan patients, 98 percent in the 1 g cefotetan patients, and 97 percent in the 2 g cefoxitin patients.

UR - http://www.scopus.com/inward/record.url?scp=0023908153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023908153&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(88)80218-6

DO - 10.1016/S0002-9610(88)80218-6

M3 - Article

VL - 155

SP - 77

EP - 80

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5 SUPPL.

ER -